Lung cancer often hides in plain sight, making early detection a critical challenge where every day counts. Respiro Diagnostics, a startup aiming to shift the standard of care with non-invasive breath-based diagnostics, has closed a $1.3M seed round.
The company is building a new standard for lung cancer detection by analyzing particles captured from breath. This cutting-edge science promises an earlier, safer, and more accessible diagnosis than current biopsy and imaging methods, designed with frontline needs in mind to move diagnostics forward.
